For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
The intersection of sports marketing and the pharmaceutical industry offers a dynamic space where brands can leverage ...
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish ...
Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...
Successfully navigating a drug development cycle is a major undertaking. On average, the sequence takes over a decade to ...
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback